Drug General Information |
Drug ID |
D0N8UE
|
Former ID |
DNC013184
|
Drug Name |
N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C13H16N2
|
Canonical SMILES |
C1=CC=C(C=C1)CCNCC2=CC=CN2
|
InChI |
1S/C13H16N2/c1-2-5-12(6-3-1)8-10-14-11-13-7-4-9-15-13/h1-7,9,14-15H,8,10-11H2
|
InChIKey |
HKFLTDDIRURSLM-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Amine oxidase [flavin-containing] B |
Target Info |
Inhibitor |
[1]
|
Amine oxidase [flavin-containing] A |
Target Info |
Inhibitor |
[1]
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
Tryptophan degradation via tryptamine
|
Dopamine degradation
|
Putrescine degradation III
|
Noradrenaline and adrenaline degradationPWY66-401:Superpathway of tryptophan utilization
|
Noradrenaline and adrenaline degradation
|
Serotonin degradation
|
Superpathway of melatonin degradation
|
Melatonin degradation II
|
KEGG Pathway
|
Glycine, serine and threonine metabolism
|
Arginine and proline metabolism
|
Histidine metabolism
|
Tyrosine metabolism
|
Phenylalanine metabolism
|
Tryptophan metabolism
|
Drug metabolism - cytochrome P450
|
Metabolic pathways
|
Serotonergic synapse
|
Dopaminergic synapse
|
Cocaine addiction
|
Amphetamine addiction
|
Alcoholismhsa00260:Glycine, serine and threonine metabolism
|
Alcoholism
|
NetPath Pathway
|
IL4 Signaling Pathway
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
5-Hydroxytryptamine degredation
|
Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
Dopamine receptor mediated signaling pathway
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
PathWhiz Pathway
|
Histidine Metabolism
|
Tyrosine Metabolism
|
Glycine and Serine Metabolism
|
Reactome
|
Norepinephrine Neurotransmitter Release Cycle
|
WikiPathways
|
Tryptophan metabolism
|
Dopamine metabolism
|
Phase 1 - Functionalization of compoundsWP706:SIDS Susceptibility Pathways
|
Biogenic Amine Synthesis
|
Oxidative Stress
|
Phase 1 - Functionalization of compounds
|
Neurotransmitter Release Cycle
|
Neurotransmitter Clearance In The Synaptic Cleft
|
Serotonin Transporter Activity
|
References |
REF 1 | J Med Chem. 2007 Mar 8;50(5):922-31. Epub 2007 Jan 26.New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. |